Nuveen LLC Takes $2.69 Million Position in Cardiff Oncology, Inc. $CRDF

Key Points

• Nuveen LLC has acquired a new position in Cardiff Oncology, Inc. ($CRDF) during the 1st quarter, purchasing 857,570 shares valued at approximately $2.69 million.
• Cardiff Oncology stock is currently down 4.1%, with a market capitalization of $138.37 million and recent earnings missing analysts' expectations.
• Several analysts maintain a consensus rating of "Moderate Buy" for CRDF, with an average target price of $10.10 amid mixed performance outlooks.

Nuveen LLC purchased a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 857,570 shares of the company's stock, valued at approximately $2,693,000. Nuveen LLC owned 1.29% of Cardiff Oncology as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in CRDF. BNP Paribas Financial Markets acquired a new position in shares of Cardiff Oncology in the 4th quarter valued at $25,000. Ledgewood Wealth Advisors LLC acquired a new stake in Cardiff Oncology during the 1st quarter worth $35,000. Castleview Partners LLC acquired a new stake in Cardiff Oncology during the 1st quarter worth $45,000. ProShare Advisors LLC acquired a new stake in Cardiff Oncology during the 4th quarter worth $50,000. Finally, Brighton Jones LLC acquired a new stake in Cardiff Oncology during the 1st quarter worth $52,000. Institutional investors and hedge funds own 16.29% of the company's stock.

Insider Activity

In other news, Director Gary W. Pace purchased 15,000 shares of the company's stock in a transaction on Wednesday, July 30th. The shares were purchased at an average price of $2.45 per share, with a total value of $36,750.00. Following the purchase, the director directly owned 1,345,676 shares of the company's stock, valued at $3,296,906.20. This trade represents a 1.13% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 7.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently commented on CRDF shares. LADENBURG THALM/SH SH started coverage on Cardiff Oncology in a research note on Tuesday, July 8th. They set a "buy" rating and a $19.00 price objective on the stock. Jefferies Financial Group started coverage on Cardiff Oncology in a research note on Tuesday, June 24th. They set a "hold" rating and a $3.50 price objective on the stock. William Blair reaffirmed an "outperform" rating on shares of Cardiff Oncology in a research note on Wednesday, June 18th. Finally, HC Wainwright dropped their price objective on Cardiff Oncology from $18.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.10.

Cardiff Oncology Price Performance

Shares of CRDF traded up $0.01 during midday trading on Wednesday, hitting $1.96. The stock had a trading volume of 1,140,923 shares, compared to its average volume of 1,117,300. The company has a 50 day simple moving average of $3.05 and a two-hundred day simple moving average of $3.24. Cardiff Oncology, Inc. has a twelve month low of $1.90 and a twelve month high of $5.64. The firm has a market cap of $130.40 million, a price-to-earnings ratio of -2.25 and a beta of 1.28.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%. The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.11 million. Analysts forecast that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.